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Abstract
Background: Differentially methylated regions (DMRs) are associated with many imprinted genes. In mice methylation at a
DMR upstream of the H19 gene known as the Imprint Control region (IC1) is acquired in the male germline and influences
the methylation status of DMRs 100 kb away in the adjacent Insulin-like growth factor 2 (Igf2) gene through long-range
interactions. In humans, germline-derived or post-zygotically acquired imprinting defects at IC1 are associated with aberrant
activation or repression of IGF2, resulting in the congenital growth disorders Beckwith-Wiedemann (BWS) and Silver-Russell
(SRS) syndromes, respectively. In Wilms tumour and colorectal cancer, biallelic expression of IGF2 has been observed in
association with loss of methylation at a DMR in IGF2. This DMR, known as DMR0, has been shown to be methylated on the
silent maternal IGF2 allele presumably with a role in repression. The effect of IGF2 DMR0 methylation changes in the
aetiology of BWS or SRS is unknown.
Methodology/Principal Findings: We analysed the methylation status of the DMR0 in BWS, SRS and Wilms tumour patients
by conventional bisulphite sequencing and pyrosequencing. We show here that, contrary to previous reports, the IGF2
DMR0 is actually methylated on the active paternal allele in peripheral blood and kidney. This is similar to the IC1
methylation status and is inconsistent with the proposed silencing function of the maternal IGF2 allele. Beckwith-
Wiedemann and Silver-Russell patients with IC1 methylation defects have similar methylation defects at the IGF2 DMR0,
consistent with IC1 regulating methylation at IGF2 in cis. In Wilms tumour, however, methylation profiles of IC1 and IGF2
DMR0 are indicative of methylation changes occurring on both parental alleles rather than in cis.
Conclusions/Significance: These results support a model in which DMR0 and IC1 have opposite susceptibilities to global
hyper and hypomethylation during tumorigenesis independent of the parent of origin imprint. In contrast, during
embryogenesis DMR0 is methylated or demethylated according to the germline methylation imprint at the IC1, indicating
different mechanisms of imprinting loss in neoplastic and non-neoplastic cells.
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Introduction
Aberrant imprinting of the Insulin-like growth factor 2 (IGF2)
gene plays a role in the pathogenesis of the overgrowth disorder
Beckwith-Wiedemann syndrome (BWS, OMIM#130650), the
growth-restriction condition Silver-Russell syndrome (SRS,
OMIM#180860), as well as various human cancers including
Wilms tumour, rhabdomyosarcoma, hepatoblastoma, colorectal
and breast carcinomas [1–6].
Mouse models have been used to demonstrate that the
imprinted expression of the closely linked Igf2 and H19 genes is
controlled by specific differentially methylated regions (DMRs) [7–
10]. One of these DMRs (the H19 DMR) is located 59 of the H19
promoter is methylated on the paternal chromosome and is known
as the imprinting control region IC1 because it functions as an
insulator mediated by the CCCTC binding factor (CTCF) [11–
14]. Deletion of the maternal IC1 results in activation of the
normally silent maternal Igf2 allele and in down-regulation of H19
[9]. In addition, a hierarchical relationship between methylation at
IC1 and Igf2 exists such that deletion or mutation within the IC1
also results in methylation changes in DMRs within the Igf2 gene
[15]. We have previously shown that IC1 actually interacts with
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manner influenced by CTCF binding and DNA methylation
[16,17]. The application of this model to the human has been
hampered by differences in the genomic organisation of IGF2
DMRs in mouse and human. Specifically, IGF2 DMR0, located 59
to the main IGF2 promoters is methylated on the maternal allele
only in placentas in the mouse [18], but has differential
methylation in all tissues in humans [19]. Methylation of the
DMR0 on the maternal IGF2 allele was inferred using cell lines
derived from a BWS patient with paternal uniparental disomy at
11p15.5 loci (UPD) [19] and in Wilms tumour kidney patients
with loss of heterozygosity of the maternal allele [20]. Methylation
analysis of the IGF2 DMR0 has been carried out in many cancer
studies following the demonstration that hypomethylation of this
DMR is associated with loss of imprinting in Wilms tumour [20]
and colorectal cancer [21]. The current interpretation of these
results is that loss of methylation at the IGF2 DMR0 plays a role in
reactivation of the silent maternal allele [21].
The molecular basis of BWS is heterogeneous with 5% of
patients exhibiting gain of methylation at IC1 with biallelic
activation of IGF2 and biallelic silencing of H19. Another group of
BWS patients has normal IC1 methylation but abnormal
methylation at IC2, a maternally methylated imprinting control
region within the KCNQ1 and KCNQ1OT1 gene cluster which
seems to operate independent of IGF2 and H19 [2]. BWS patients
with IC1 defects have a particularly high predisposition to
developing Wilms tumour, while those patients with IC2 defects
are apparently more at risk for other tumours [2,22]. Hyper-
methylation at the IC1 is also a frequent feature in non-syndromic
Wilms tumour patients which together with the distinct tumour
predisposition profiles in BWS patients suggest that similar
epigenetic defects lead to soma-wide overgrowth and cancer.
SRS also has a complex heterogeneous molecular aetiology and a
subset of individuals has loss of methylation at IC1 with biallelic
silencing of IGF2 and biallelic activation of H19 [6].
To date there have been no reports on the methylation status of
the IGF2 DMR0 region in BWS and SRS patients and it is not
known to what extent the proposed silencing function of this DMR
contributes to the aetiology of BWS and SRS. We therefore
examined parent of origin methylation at the DMR0 in various
subtypes of BWS and SRS patients and also in a cohort of Wilms
tumour samples. Our results indicate that the active paternal IGF2
allele is methylated at the DMR0 in cis with H19 methylation in
normal individuals and that in SRS and BWS the DMR0 and IC1
have similar methylation abnormalities. In contrast, in Wilms
tumour samples DMR0 methylation is negatively correlated with
IC1 methylation. These results imply IGF2 imprinting defects in
congenital growth disorders and Wilms tumours arise through
different epigenetic mechanisms.
Results
IGF2 DMR0 methylation status in BWS and SRS patients
We examined the methylation status of DMR0 in peripheral
blood leukocyte DNA derived from BWS patients with IC1
hypermethylation (n= 7), IC2 hypomethylation (n=37) or
normal methylation at both IC1 and IC2 (n=27) and SRS
patients with IC1 hypomethylation (n= 2), using bisulphite and
pyrosequencing analysis. The region analysed is shown in
figure 1A. To our surprise, 6/7 BWS patients with hypermethyla-
tion at IC1 also had hypermethylation at DMR0 (Median
methylation 69.2%, interquartile range (IQR) 60.5%; 75.1%)
and 2/2 SRS with IC1 hypomethylation also had DMR0
hypomethylation (28.2% and 36.28%). Patients with normal
methylation at IC1 or hypomethylation at IC2 had normal
methylation levels at DMR0 (Median methylation 53%; IQR
48.2%, 57.1%). These results suggest that either methylation
changes in BWS and SRS were occurring in trans or that
methylation at the DMR0 is on the paternal allele.
To distinguish between these possibilities, we examined 13 BWS
patients with excess copies of paternal 11p15.5 (12 patients had
paternal UPD and one patient had an 11p15.5 duplication) and
two SRS patients with maternal 11p15.5 duplications. We also
determined directly the parental origin of methylation at the IGF2
DMR0 in some of our BWS and SRS patients and 6 control
individuals in order to confirm our findings. The patients with
maternal duplication had reduced methylation levels (44%), while
all the paternal UPD and the paternal duplication patients had
hypermethylation ((Median methylation 60.2%; IQR 56.1%,
64.3%), Fig. 1B). In all informative families we were able to
confirm that the paternal allele was preferentially methylated at
the DMR0 (particularly the CpGs 15–17) in cis with methylation
at the IC1 (Fig. 1C and Fig. S1). These results therefore suggest
that methylation at the IC1 influences methylation at the IGF2
DMR0. BWS and SRS cases with methylation defects at the IC1
acquire the same methylation defect at the DMR0 in the germline
or early fetal development such that the maternal IGF2 allele gains
methylation and is activated (BWS) or the paternal allele fails to
become methylated and is silenced (SRS). These allele-specific
methylation changes have the effect of an imprint switch so that
both alleles look like either a paternal allele (BWS) or a maternal
allele (SRS). Pyrosequencing results were verified by bisulphite
sequencing (Fig. S1).
IGF2 methylation analysis in Wilms Tumour samples
We analysed DMR0 methylation in two Wilms tumour patients
that had arisen in individuals affected by BWS and a series of non-
syndromic Wilms tumour patients. One of the BWS patients had
constitutional hypermethylation at IC1, the other had paternal
UPD. The non-syndromic Wilms tumour patients comprised of
individuals that had tumour-specific IC1 hypermethylation
(n=10), 11p15.5 LOH with loss of the maternal allele (n=13)
or normal methylation (n=10) at the IC1. Remarkably, all
tumours with hypermethylation at IC1 and most of those with
LOH, including those arisen in individuals affected by BWS,
showed reduced methylation at DMR0 (Median methylation
24.8%, IQR 16.52, 34,9), while those with normal IC1
methylation had normal DMR0 methylation (Median methylation
45.1%, IQR 34.2; 52.3) (Fig. 2A–B). Indeed, a significant inverse
correlation (Pearson r=0.7118, CI -8718-0.4146) could be shown
between DMR0 and IC1 methylation levels in Wilms tumour
patient (Fig. 2C). As in blood leukocytes, adjacent non tumour
tissue showed predominant methylation of the paternal allele
(Fig. 2D and data not shown). These results show distinct
epigenetic changes in Wilms tumour compared to congenital
growth disorders.
Discussion
The results of our genetic studies demonstrate that DMR0 is
methylated on the paternal allele contradicting the conclusions of
two previous studies which have reported that DMR0 methylation
is on the maternal allele [19,20]. In the first report methylation
was investigated for the entire IGF2 gene in Wilms tumour samples
with and without loss of imprinting [20]. In this study, differential
methylation at the DMR0 region was shown in normal kidney and
in tumours with monoallelic expression, whereas tumours with loss
of imprinting, were hypomethylated [20]. The CpGs that we
Innate and Tumour Methylation
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authors using MspI/ HpaII restriction analysis (Figure 1) and the
region is spanned by probe 9 in figures 1 and 3 in [20]. In four
cases with loss of heterozygosity of 11p15.5 where the maternal
allele was lost, the retained paternal allele was found to be
unmethylated and thus the maternal allele was inferred to be the
normally methylated allele [20]. We examined 13 cases with LOH
and showed similar hypomethylation patterns, which suggests that
cells with LOH are inclined to methylation changes at the DMR0
as a result of being tumours. The second study to report that
DMR0 is maternally methylated characterised novel transcripts of
IGF2 during development. These authors examined a cell line
established from pUPD patient and found that the DMR0 was
hypomethylated [19]. We have found that DMR0 tends to be
demethylated in hybridoma cell lines with a single human
chromosome 11, regardless of parental origin (unpublished
observation) and assume that this may be a cell culture
phenomenon.
The function of DMR0 is still unknown. It has been postulated
that the role of DMR0 methylation is to maintain silencing on the
maternal IGF2 allele. However, the knowledge that the parental
origin of IGF2 DMR0 methylation is paternal eliminates a role in
methylation-mediated repression of the maternal IGF2 allele.
Indeed rather than acting as an autonomous regulator of
imprinting, our results suggest that the DMR0 methylation is
influenced by IC1 methylation in non-neoplastic cells. Thus
during embryogenesis, parent of origin specific methylation
patterns at the human IGF2-H19 locus are established in cis
similar to observations in mice [15].
In mice where CTCF sites have been mutated, the exclusion of
CTCF from the maternal IC1 has resulted in methylation of the
IC1 [23] and Igf2 DMRs [16]. Furthermore, in adult mouse
choroid plexus, a brain tissue in which Igf2 is expressed from both
alleles and H19 is not expressed, IC1 and the Igf2 DMRs are
methylated on both parental chromosomes [24]. We show here
that aberrant gain or loss of methylation at the IC1 is coupled to
the same methylation change at IGF2 DMR0. The main
difference is that mice have a DMR1 and a placenta specific
DMR0, whereas in humans, DMR1 is lacking and the DMR0
seems to behave more similar to mouse DMR1. The ultimate
effect of IC1 influencing IGF2 methylation is that epimutation of
IC1 has the consequence of both parental alleles displaying a
paternal imprint in the case of BWS or a maternal imprint in the
case of SRS (Fig. 3).
If long-range interactions between DMRs at this locus are
similar in mice and humans, this would explain the imprinting
defects that are found in the overgrowth disorders BWS and SRS.
However, the imprinting defects in Wilms tumour remain difficult
to reconcile with enhancer competition and long-range DMR
interaction models. In our analysis of this selected group of Wilms
tumour patients, methylation at the DMR0 is lost on the paternal
allele, while IC1 gains methylation on the maternal allele. DMR0
methylation levels are particularly low in some of the tumours,
indicating an almost complete eradication of methylation at this
site probably from both alleles (Fig. 2A–C). Epigenetic repro-
gramming thus occurs on both parental chromosomes rather than
in cis, indicating that different mechanisms control IGF2
imprinting in neoplastic and non-neoplastic cells (Fig. 3). Soma-
wide IC1 hypermethylation in BWS predisposes to Wilms tumour
and similar epigenetic changes occurs in the kidney as pre-
neoplastic events in Wilms tumorigenesis [25]. It is possible that
DMR0 hypomethylation is associated with a more sustained
activation of IGF2 in tumour cells as a result of alternative high
level chromatin conformation promoted by tumour-specific
activators.
During tumorigenesis global hypomethylation occurs in repeat
rich regions, LINE and SINE elements, while CpG islands
associated with promoters are subject to hypermethylation [26].
DMRs methylated in the germline and DMRs methylated in the
somatic cells may differ in their ability to be reprogrammed
during tumorigenesis. Further comparison of different DMRs in
terms of germline versus somatic and maternally versus paternally
methylated as well as genetic and epigenetic characteristics
should lead to deeper understanding of epigenetic reprogram-
ming in cancer. Prior to our studies, loss of methylation is the
only described epimutation at the DMR0 in cancers, while both
hyper and hypomethylation has been described at the IC1
[21,27]. Moreover, not all reports show a direct correlation
between IGF2 expression and DMR0 methylation changes at this
locus and we have reported exceptions in breast cancer (Ito et al.
submitted), while others have reported exceptions in ovarian and
bladder cancer [28,29]. Those studies that do show a relationship
between loss of DMR0 methylation and loss of imprinting need to
be reinterpreted because the methylation at the DMR0 region is
lost from the active paternal allele rather than from the silent
allele.
In summary, we show three different reprogramming events
occurring at the IGF2-H19 locus and associated with imprinting
loss in BWS, SRS and Wilms Tumour. In the growth disorders,
germline allele-specific methylation changes have the effect of an
imprint switch so that both alleles look like either a paternal allele
(BWS) or a maternal allele (SRS) while in cancer both parental
marks are lost and reprogrammed. Our findings demonstrate that
loss of IGF2 imprinting is a complex phenomenon that occurs with
different mechanisms in human disease, probably reflecting
different molecular causes and responses.
Figure 1. IGF2 DMR0 Methylation levels in Beckwith-Wiedemann Syndrome (BWS) and Silver-Russell Syndrome (SRS) patients. A.
Location of DMR0 within the IGF2 gene relative to the paternally methylated imprinting control region IC1 which is upstream of H19. Pyrosequencing
was used to analyse methylation at six CpGs within the DMR0 region (NCBI 36: 11, 2125904–2126160, containing SNP rs3741210). Bisulphite (BSQ)
and pyrosequencing (PSQ) primer positions are as indicated. This region contains the CpGs (numbered 15,16,17) marked in grey which have
previously been published to be hypomethylated in Colorectal cancer [21]. Vertical lines indicate MspI/HpaII sites in the DMR0. B. Box plot showing
medians, IQR, max. and min. values for IGF2 DMR0 methylation levels as measured by pyrosequencing of bisulphite converted DNA obtained from
peripheral blood samples from BWS and SRS patients. Methylation percentages reflect the proportion of bisulphite converted cytosines at the CpGs
measured in the assay. Normal methylation levels for imprinted DMRs are 45–55% (see C). Categories of BWS patients included those with: no
imprinting defect at the IC1 region and the IC2 region (NM); low methylation (LM) at the IC2 (IC2-LM); increased paternal 11p15 through paternal
duplication or uniparental disomy (pUPD); and hypermethylation at IC1 (IC1-HM). SRS patients included two each of maternal duplication of 11p15
(Mat Dup) and hypomethylation at IC1 (IC1-LM). BWS with hypermethylation at the IC1, also have hypermethylation at DMR0, while SRS with
hypomethylation IC1 have hypomethylation at DMR0. C. Parent of origin specific methylation in normal, BWS and SRS patients. The BWS and SRS
patients have imprinting defects at IC1. Bisulphite converted DNA was amplified with allele-specific primers for the rs3741210 polymorphism in IGF2
DMR0 prior to pyrosequencing for methylation. The T allele is shown by squares and C alleles shown by triangles in the plots. Circles show the
percentage of total methylation of the CpGs assayed. The paternal allele is more methylated at DMR0 than the maternal allele. Both alleles are
hypermethylated in BWS and both alleles are hypomethylated in SRS.
doi:10.1371/journal.pone.0001849.g001
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PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1849Figure 2. Methylation levels at the IGF2 DMR0 region in Wilms tumour patients. A. Box plot showing medians, IQR, max. and min. values
for IGF2 DMR0 methylation levels as measured by pyrosequencing of peripheral blood (open box), normal kidney (hatched box) and tumour biopsies
(grey box) from Wilms Tumour patients that do not have BWS. Methylation percentages reflect the proportion of bisulphite converted cytosines at
the CpGs measured in the assay. Normal methylation levels for imprinted DMRs are 45–55% (see D). Wilms Tumour patient samples include
peripheral blood and tumour DNA from patients with normal methylation at IC1 in their tumours (NM); peripheral blood, normal kidney and tumour
DNA samples from patients with hypomethylation of IC1 in their tumours (IC1-HM); and tumour DNA samples from patients with loss of
heterozygosity (LOH) in their tumours. Strikingly, Wilms Tumour patients with hypermethylation at IC1 have hypomethylation at DMR0 in their
tumours. B Methylation levels in peripheral blood, unaffected kidney tissue and Wilms tumour kidney tissue from two BWS patients (one with IC1
hypermethylation and one with pUPD). Both patients have hypomethylation of IGF2 DMR0 in their tumours. C Linear regression curve showing
inverse relationship between methylation levels at the IC1 and DMR0 in Wilms Tumour. Tumours with hypermethylation at the IC1 have loss of
methylation at DMR0. D. Peripheral blood and kidney tissue from a patient with Wilms Tumour that does not have hypermethylation at IC1. The C-
allele is hypermethylated, while the T-allele is hypomethylated in both the blood and kidney–indicating similar parent of origin methylation in these
tissues.
doi:10.1371/journal.pone.0001849.g002
Innate and Tumour Methylation
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Subjects
85 BWS and 3 SRS cases were recruited from different Italian
Pediatric Departments and were clinically diagnosed according to
the criteria described in the literature (http://www.geneclinics.
org). The study also involved 40 Wilms Tumour patients enrolled
by Paediatric Oncology Units affiliated to Associazione Italiana
Ematologia Oncologia Pediatrica (AIEOP). All tumours were
histologically diagnosed.
Ethical Approval
This study was approved by the ethical committees of the
Second University of Naples and Istituto Nazionale Tumori, INT,
Milan .
Identification of IC1 and IC2 methylation, UPD, LOH and
copy number abnormalities
The DNA methylation at IC1 and IC2 was analysed by
Southern blotting with methylation-sensitive restriction enzymes
or COBRA, as described [2]. Three samples with IC1 hyper-
methylation derived from BWS patients also had inherited
microdeletions [30,31]. UPD, LOH and duplication at 11p15.5
loci were determined by microsatellite analysis, as described [32].
Analyses of DMR0 methylation
We designed a standard pyrosequencing assay for IGF2 DMR0
region (NCBI36:11,2125904-2126160) which included six CpGs,
three of which were previously reported to be hypomethylated in
colorectal patients with LOI at IGF2 [21]. The CpGs within this
region are included in the DMR0 region analysed by others
[19,20]. 100 ng–2 ug of genomic DNA per sample was bisulphite
treated using EZ DNA methylation kit (Zymo Research).
Bisulphite treated DNA was used for generating PCR amplified
templates for pyrosequencing using the following forward primer:
59TGAGGATGGGTTTTTGTTTGGTAT39 and biotinylated
reverse primer 59TCCTCAATCCACCCAAAATAATAT39.
10 uL of the biotinylated PCR product was used for each
sequencing assay using the following sequencing primers
59GGGGTGGAGGGTGTA 39 and 59-AAAAGTTATTGGA-
TATATAGT 39. Pyrosequencing was carried on PSQ HS 96
System and PyroMark MD System using Pyro Gold Reagent kits
(Biotage, Uppsala, Sweden). Allele-specific pyrosequencing was
carried out by replacing the above biotinylated primer with allele-
Figure 3. Summary of IGF2 DMR0 Methylation relative to IC1 in normal, congenital growth disorders and Wilms tumour. In normal
individuals, IGF2 expression is from the paternal allele and H19 is from the maternal allele. IC1 and DMR0 are methylated on the paternal
chromosome. In BWS, the epigenotype and expression pattern of the maternal chromosome are converted to paternal and in SRS, the epigenotype
and expression pattern of the paternal chromosome are converted to maternal (imprint switching). In the Wilms tumour, IGF2 activation and H19
silencing are associated with disruption of both maternal and paternal imprints (somatic loss of imprinting).
doi:10.1371/journal.pone.0001849.g003
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TAAAAAAAAAATTCAC39,o r5 9CCCAAAATAATATCTA-
TAAAAAAAAAATTCAT39 which recognized the G or A allele
of the rs3741210 polymorphism on the reverse strand after
bisulphite conversion.
Methylation was quantified using Pyro Q-CpG Software
(Biotage, Uppsala, Sweden) that calculates the ratio of converted
C’s (T’s) to unconverted C’s at each CpG and expresses this as a
percentage methylation. Average methylation across the DMR0
for all 6 CpGs were calculated. Median and IQR methylation for
different categories of patients were analysed using Prism
Graphpad software.
We verified allele-specific methylation by conventional bisul-
phite sequencing of cloned PCR products in all our informative
cases.
Supporting Information
Figure S1 Bisulphite sequencing analyses of IGF2 DMR0
Methylation in normal, congenital growth disorders and Wilms
Tumour. IGF2 DMR0 Methylation in normal, congenital growth
disorders and Wilms Tumour. Methylation of 6 CpGs was
determined by bisulphite genomic sequencing on DNA extracted
from peripheral blood leukocytes (Normal, BWS and SRS) or
tumour tissue (Wilms Tumour) of individuals informative for the
rs3741210 polymorphism. Filled circles represent methylated
CpGs and open circles unmethylated CpGs. The maternal
(MAT) and paternal (PAT) alleles of the IGF2 DMR0 region
are indicated.
Found at: doi:10.1371/journal.pone.0001849.s001 (1.33 MB TIF)
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